Pharnext S.A.

  • WKN: A2AM02
  • ISIN: FR0011191287
  • Land: Frankreich

Nachricht vom 13.09.2017 | 17:47

Pharnext to Present at 7th Annual CEC Capital Summit

DGAP-News: Pharnext S.A. / Key word(s): Conference

13.09.2017 / 17:47
The issuer is solely responsible for the content of this announcement.


Pharnext to Present at 7th Annual CEC Capital Summit

Paris, France, 5:45pm, September 13, 2017 (CEST) - Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the 7th Annual CEC Capital Summit.

The presentation will take place as follows:

  • Date: Wednesday, September 20th, 2017
  • Time: 2:50 pm PDT (11:50 pm CEST)
  • Venue: Montage Beverly Hills in Beverly Hills, California

If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY(TM). The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG(TM) offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.


The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit www.pharnext.com

CONTACTS:

Pharnext
Xavier Paoli
Chief Commercial Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
 
   
Investor Relations (Europe)
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22
 
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1 212-362-1200
 
Financial Communication (France)
New CAP
Emmanuel Huynh
pharnext@newcap.eu
+33 (0)1 44 71 20 40
 
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com  
+33 (0)1 44 54 36 64
 
 
Media Relations (U.S.)
Russo Partners
Tony Russo
Scott Santiamo
tony.russo@russopartnersllc.com 
scott.santiamo@russopartnersllc.com 
+1 212-845-4251
+1 718-344-5843
 


13.09.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC im Fokus

The Grounds-Gruppe: Ein attraktiver Immobilienbestandshalter entsteht

Die The Grounds-Gruppe führt eine Kapitalerhöhung von bis zu 11,2 Mio. € durch. Der Erlös soll für den Aufbau des Immobilienbestands verwendet werden. Parallel dazu soll auch der Development-Bereich ausgebaut werden. Die Gesellschaft verfügt derzeit über fünf vertraglich gesicherte Entwicklungsprojekte sowie über weitere Projekte in einer fortgeschrittenen Verhandlungsphase mit einem Volumen von über 370 Mio. €. Das erfahrene Management hat demnach die Basis für weiteres Umsatz- und Ertragswachstum gelegt. Wir haben ein Kursziel von 5,40 € ermittelt, welches deutlich oberhalb des aktuellen Platzierungspreises von 2,20 € liegt. Das Rating lautet KAUFEN.

Aktuelle Research-Studie

Vita 34 AG

Original-Research: Vita 34 AG (von Montega AG): Kaufen

23. November 2017